3-bromo-3-butenyl tert-butyldiohenylsilyl ether | 144543-35-1

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 3-bromo-3-butenyl tert-butyldiohenylsilyl ether
• 英文别名: 2-bromo-4-tert-butyldiphenylsilyloxybutene；((3-bromobut-3-en-1-yl)oxy)(tert-butyl)diphenylsilane；(3-bromobut-3-enyloxy)(tert-butyl)diphenylsilane；[(3-bromo-3-buten-1-yl)oxy](1,1-dimethylethyl)diphenylsilane；3-bromobut-3-enoxy-tert-butyl-diphenylsilane
• CAS: 144543-35-1
• 化学式: C₂₀H₂₅BrOSi
• 分子量: 389.407
• InChiKey: BCZMRVNGRDCQDU-UHFFFAOYSA-N

物化性质

• 沸点：
  398.8±42.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-bromo-3-butenyl tert-butyldiohenylsilyl ether 在 sodium tetrahydroborate 、 叔丁基锂 作用下， 以 乙醇 为溶剂， 反应 4.08h， 生成 1-丁醇,4-[[(1,1-二甲基乙基)二苯基甲硅烷基]氧代]-2-亚甲基-
  参考文献：
  名称：

  Myers, Andrew G.; Dragovich, Peter S.; Kuo, Elaine Y., Journal of the American Chemical Society, 1992, vol. 114, # 24, p. 9369 - 9386

  摘要：

  DOI：
• 作为产物：
  描述：

  3-溴-3-丁烯醇 、 叔丁基二苯基氯硅烷 在 咪唑 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以100%的产率得到3-bromo-3-butenyl tert-butyldiohenylsilyl ether
  参考文献：
  名称：

  Synthesis of Highly Substituted Symmetrical 1,3-Dienes via Organocuprate Oxidation

  摘要：

  由烯基卤化物形成的烯基有机铜酸盐发生氧化反应，可生成高度取代的对称 1,3 二烯。由有机锂和格氏试剂形成的铜酸盐也可以耐受，而且反应进行时烯基的几何形状得以保留。

  DOI：

  10.1055/s-0031-1290116

文献信息

• The first synthetic studies on pestalotiopsin A. A stereocontrolled approach to the functionalised bicyclic coreElectronic supplementary information (ESI) available: crystal structure analysis of 18a. See http://www.rsc.org/suppdata/ob/b2/b209066j/
  作者：Derek Johnston、Emmanuel Couché、David J. Edmonds、Kenneth W. Muir、David J. Procter

  DOI：10.1039/b209066j

  日期：2003.1.13

  structurally unique, caryophyllene-type sesquiterpene which has shown immunosuppressive activity and cytotoxicity in preliminary assays. A stereocontrolled approach to the functionalised 2-oxabicyclo[3.2.0]-heptane core of pestalotiopsin A is described. This constitutes the first synthetic studies on pestalotiopsin A. Our approach includes a samarium(II)-mediated 4-exo-trig cyclisation and a trans-lactonisation

  骨视蛋白A是一种结构独特的，石竹烯型倍半萜，在初步试验中显示出免疫抑制活性和细胞毒性。描述了一种立体控制的方法来合成鼠疫视蛋白A的2-氧杂双环[3.2.0]-庚烷核心。这构成了对瘟疫菌素A的首次合成研究。我们的方法包括includes（II）介导的4-exo-trig环化和通过向环丁酮中间体中添加烷基y试剂而引发的反式内酯化过程。进一步的操作提供了进入高级中间体的途径，这些中间体是未来构建靶最终环的极好前体。
• A new ground state single electron donor for excess electron transfer studies in DNA
  作者：Christian Trindler、Antonio Manetto、Jürgen Eirich、Thomas Carell

  DOI：10.1039/b906180k

  日期：——

  A new photoinducible single electron donor has been developed, which, when linked to thymidine, is shown to be an efficient ground state reducing agent in DNA; the donor can be activated at wavelengths where standard DNA does not absorb.

  一种新的可光诱导单电子供体已被开发，当其与胸苷连接时，显示出在DNA中作为有效的基态还原剂；该供体可以在标准DNA不吸收的波长下被激活。
• Synthesis of Highly Substituted Symmetrical 1,3-Dienes via Organocuprate Oxidation
  作者：David Spring、Sarah. Aves、Kieron O’Connell、Kurt Pike

  DOI：10.1055/s-0031-1290116

  日期：2012.1

  Oxidation of alkenyl organocuprates formed from alkenyl halides allows the formation of highly substituted symmetrical 1,3-dienes. Cuprates formed from organolithiums and Grignard reagents can be tolerated and the reaction proceeds with retention of alkenyl geometry.

  由烯基卤化物形成的烯基有机铜酸盐发生氧化反应，可生成高度取代的对称 1,3 二烯。由有机锂和格氏试剂形成的铜酸盐也可以耐受，而且反应进行时烯基的几何形状得以保留。
• CHEMICAL COMPOUNDS
  申请人：Di Fabio Romano

  公开号：US20080114049A1

  公开（公告）日：2008-05-15

  The present invention relates to (1S,6R)-6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane, pharmaceutically acceptable salts, prodrugs or solvates thereof; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.

  本发明涉及(1S,6R)-6-(3,4-二氯苯基)-1-[(甲氧基)甲基]-3-氮杂双环[4.1.0]庚烷，其药学上可接受的盐、前药或溶剂化物；用于其制备的中间体，含有它们的制药组合物以及它们在治疗中的应用，作为5-羟色胺(5-HT)、多巴胺(DA)和去甲肾上腺素(NE)的再摄取抑制剂。
• AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE
  申请人：Bertani Barbara

  公开号：US20100035914A1

  公开（公告）日：2010-02-11

  The present invention relates to novel compounds of formula (I)′, and pharmaceutically acceptable salts, prodrugs or solvates thereof: wherein R 1 is hydrogen or C 1-4 alkyl; R 2 is a group A, K or W wherein A is K is an α or β naphthyl group, optionally substituted by 1 or 2 groups R 18 , each of them being the same or different; and W is and wherein G is a 5,6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; wherein G may be substituted by (R 15 ) p , which can be the same or different; p is an integer from 0 to 5; R 3 is selected from the group consisting of: hydrogen, fluorine, and C 1-4 alkyl; or corresponds to a group X or X 1 ; R 4 is selected from the group consisting of: hydrogen, fluorine, and C 1-4 alkyl; or corresponds to a group X or X 1 ; R 5 is hydrogen or C 1-4 alkyl; R 7 is hydrogen or C 1-4 alkyl; or is a group X, X 1 , X 2 or X 3 ; wherein X is X 1 is X 2 is and X 3 is R 6 is hydrogen or C 1-4 alkyl; or is a group X or X 1 ; R 9 is C 1-4 alkyl; R 10 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy and C 1-4 alkanoyl; R 11 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 12 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 13 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 14 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 15 is selected from the group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 16 is hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl or C 3-6 cycloalkylC 1-3 alkyl; R 17 is hydrogen or C 1-4 alkyl; R 18 is selected from the group consisting of: halogen, cyano, and C 1-4 alkyl; R 19 is haloC 1-2 alkyl; and n is 1 or 2; with the proviso that: if R 2 is A, R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 13 , and R 14 are hydrogen, and R 12 is fluorine, R 1 is C 1-4 alkyl; if R 2 is A, R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 13 , and R 14 are hydrogen, and R 1 is methyl, R 12 is halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl or SF 5 ; or corresponds to a group R 8 ; and processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.

  本发明涉及式(I)'的新化合物，以及其药学上可接受的盐、前药或溶剂化物： 其中， R1为氢或C1-4烷基； R2为A、K或W基团，其中 A为 K为α或β萘基团，可选地被1或2个R18基团取代，每个基团相同或不同； W为 其中， G为5,6-成员单环杂芳基团或8-至11-成员杂芳双环基团；其中G可能被(R15)p取代，其中p可以是0到5的整数；R3选择自氢、氟和C1-4烷基；或对应于X或X1基团； R4选择自氢、氟和C1-4烷基；或对应于X或X1基团； R5为氢或C1-4烷基； R7为氢或C1-4烷基；或为X、X1、X2或X3基团； 其中， X为 X1为 X2为 且X3为 R6为氢或C1-4烷基；或为X或X1基团； R9为C1-4烷基； R10选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R8为5-6成员杂环基团，可以被来自卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基和C1-4酰基的一或两个取代基团取代； R11选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R12选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R13选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R14选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R15选择自卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R16为氢、C1-4烷基、C3-6环烷基或C3-6环烷基C1-3烷基； R17为氢或C1-4烷基； R18选择自卤素、氰基和C1-4烷基； R19为卤代C1-2烷基；且 n为1或2； 但前提是，如果R2为A，R3、R4、R5、R6、R7、R10、R11、R13和R14为氢，而R12为氟，R1为C1-4烷基；如果R2为A，R3、R4、R5、R6、R7、R10、R11、R13和R14为氢，而R1为甲基，R12为卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基或SF5；或对应于R8基团；以及用于制备它们的过程、用于这些过程的中间体、含有它们的制药组合物以及它们在治疗中的应用，作为5-羟色胺（5-HT）、多巴胺（DA）和去甲肾上腺素（NE）的再摄取抑制剂。